DANIEL M. BRADBURY, DMS
Mr. Bradbury is the Managing Member of BioBrit, LLC, a life sciences consulting and investment firm in La Jolla, California and formerly, the President and Chief Executive Officer of Amylin Pharmaceuticals, Inc. Mr. Bradbury has nearly 30 years of pharmaceutical industry experience. During his 18-year tenure at Amylin, the company launched three first-in-class medicines: Symlin, Byetta and Bydureon. He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb in August 2012. Before joining Amylin, Mr. Bradbury held marketing and sales positions for ten years at SmithKline Beecham Pharmaceuticals. Mr. Bradbury currently serves on the board of directors of Corcept Therapeutics (NASDAQ: CORT), Geron Corporation (NASDAQ: GERN), Illumina, Inc. (NASDAQ: ILMN), BioMed Realty (NYSE: BMR), Biocon Limited (NSE: BIOCON), Castle Biosciences, Inc. (Private), DiaVacs (Private), Microdermis, Inc. (Private) and Profil Institute for Clinical Research (Private). He also serves on the board of trustees of the Keck Graduate Institute, the Investor Growth Capital Advisory Board, the BioMed Ventures Advisory Committee, the University of California San Diego’s Rady School of Management’s Advisory Council and the University of Miami’s Innovation Corporate Advisory Council. Mr. Bradbury received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
MARVIN CARUTHERS, PHD
Marvin H. Caruthers, Ph.D., is a Distinguished Professor of Chemistry and Biochemistry at the University of Colorado and a pioneer in the biotechnology field. One of the co-founders of Amgen and Applied Biosystems, Dr. Caruthers’ groundbreaking scientific research in nucleic acid chemistry led to the development of DNA synthesizing techniques that remain the industry standard today. Dr. Caruthers is also a founding investor in miRagen Therapeutics and member of the Board. Dr. Caruthers holds a B.S. in Chemistry from Iowa State University and a Ph.D. in Biochemistry from Northwestern University. A Guggenheim Fellow, he is a member of the National Academy of Sciences and the American Academy of Arts and Sciences. Dr. Caruthers was awarded the National Medal of Science for 2006, the nation’s highest distinction honoring scientific achievement.
GILAD S. GORDON, MD, MBA
Dr. Gilad S. Gordon serves as Clinical Associate Professor of Medicine at the University of Colorado Health Sciences Center and is a Principal of the ORRA Medical Consulting Group, providing expertise in the development and implementation of clinical trial programs in the biotechnology and pharmaceutical industries. Dr. Gordon brings over 20 years of Industrial and Academic experience, including tenures at Eli Lilly Company, Synergen, Ribozyme Pharmaceuticals, and FeRx. Dr. Gordon is a recognized authority in the areas of new drug research and development, clinical trial design and execution, and regulatory compliance in the healthcare industry, focusing on the areas of oncology, hepatology, and immunology. He has received awards of recognition from Harvard Medical School, the American College of Physicians, and the American College of Chest Physicians. Dr. Gordon received his A.B. in Biochemistry from Harvard University, his M.D. from Harvard University/Massachusetts Institute of Technology, and his M.B.A from the University of Washington. In addition to serving on the board of directors of the Caring for Colorado Foundation, and the University of Colorado Institutional Review Board, Dr. Gordon is an active attending physician at the Denver Veteran’s Administration Hospital.
ROBERT S. HODGES, PHD
Dr. Hodges is a Professor of Biochemistry and Molecular Genetics and holder of the John Stewart Endowed Chair in Peptide Chemistry at the University of Colorado, School of Medicine. At the University of Alberta he became a founding member of the Medical Research Council of Canada Group on Protein Structure and Function, Director of the Alberta Peptide Institute and Network Leader of the Protein Engineering Network of Centres of Excellence, a national network. Dr. Hodges has received many awards among which are the distinguished MRC Scientist Award (considered to be the most prestigious of such awards in Canada), the Boehringer-Mannheim Award from the Canadian Society of Biochemistry and Molecular Biology (in recognition of a record of outstanding achievement in research in the field of Biochemistry), the Vincent du Vignead Award from the American Peptide Society (for outstanding achievements in peptide research) and in 2009 Inventor of the Year award at the University of Colorado Denver. In addition, he has been President and CEO, member of Boards of Directors, and consultant to many biotech companies. His research interests are diverse with over 500 publications and 48 patents/patent applications to his credit.
THOMAS KEUER, MS
Mr. Keuer brings over 30 years of technical expertise in the biotechnology and pharmaceutical industries, including leadership positions with ARCA biopharma, Insmed, Baxter International, Somatogen and Monsanto. In his current position with ARCA, Tom has overall responsibility for the company’s technical development programs in the chemistry, manufacturing and controls (CMC) area, and also serves as the head of project management. Prior to ARCA, he was Senior Vice President of Insmed Therapeutic Proteins, with responsibility for all process development and manufacturing programs at the company, including leadership of the GMP manufacturing site in Boulder, CO. Prior to Insmed, Tom was Vice President of Engineering for Baxter International’s Bioscience Division, a position that involved global responsibility for all capital projects related to manufacturing of biotechnology products. Tom also served as Vice President of Manufacturing for Somatogen, Inc, a Boulder-based biotechnology company. He received his Masters of Science in Biochemical Engineering from Rice University as a Monsanto–sponsored delegate.
WILLIAM S. MARSHALL, PHD
Dr. Marshall is currently miRagen’s President & CEO, Co-Founder and Director. Prior to establishing miRagen, Dr. Marshall was Vice President of Technology and Business Development for Bioscience at Thermo Fisher Scientific. Dr. Marshall was one of the scientific founders of Dharmacon, Inc., which was acquired by Fisher Scientific International, serving as the Executive Vice President for Research and Operations and General Manager. Prior to joining Dharmacon, Dr. Marshall served in many capacities at Amgen, Inc., most recently as Associate Director of Research, Site Head for Research and Head of the Nucleic Acid and Peptide Technology Department. Dr. Marshall earned his B.S. in Biochemistry from the University of Wisconsin-Madison and his Ph.D. in Chemistry in the laboratory of Professor Marvin Caruthers at the University of Colorado at Boulder. He is author and co-author of over 50 research papers and 80 patents. Dr. Marshall currently serves on the Board of BiOptix, Inc.
DAVID L. SNITMAN, PHD
Dr. Snitman is currently a principal at DL SNITMAN LLC, a consulting firm providing business development services to the biotechnology industry. Dr. Snitman is a co-founder of Array BioPharma and served as Chief Operating Officer & Vice President, Business Development from 1998 to 2015. While at Array, he was responsible for negotiation numerous deals with major pharmaceutical companies including Eli Lilly, AstraZeneca, Celgene to name a few. He was a member of Array’s Board of Directors from May 1998 to October 2012. Prior to forming Array, Dr. Snitman held senior positions with Amgen Inc. including Associate Director, New Products and Technology, and Manager of Amgen’s Boulder research facility. Dr. Snitman received a B.S. in chemistry from Northeastern University and obtained a Ph.D. in the synthesis of natural products from the University of Colorado. He was an NIH Postdoctoral Fellow at the Massachusetts Institute of Technology.